Precise role of acid in non-erosive reflux disease

Digestion

Volumn 78, Issue SUPPL. 1, 2008, Pages 31-41

  Wang, Changcheng ^a   Hunt, Richard H ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Acid; Erosive esophagitis; Gastroesophageal reflux disease; Non erosive reflux disease; Response to acid suppression

Indexed keywords

ANTACID AGENT; PEPSIN A; PROTON PUMP INHIBITOR;

ACIDITY; CELL DAMAGE; CONFERENCE PAPER; DISEASE DURATION; DRUG HALF LIFE; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; HYPERALGESIA; HYPOTHESIS; NON EROSIVE REFLUX DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PH MEASUREMENT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH ACID; STOMACH ACID SECRETION; SYMPTOM; TREATMENT RESPONSE;

ESOPHAGEAL PH MONITORING; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; INTESTINAL MUCOSA; PROTON PUMP INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 53349109508     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151253     Document Type: Conference Paper

References (89)

1. Fass R: Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007;41:131-137.
2. Dent J, El-Serag HB, Wallander MA, et al: Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-717.
3. Fock KM, Talley NJ, Fass R, et al: Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol 2008;23:8-22.
4. Dent J, Brun J, Fendrick AM, et al: An evidence-based appraisal of reflux disease management. The Genval workshop report. Gut 1999;44:S1-S16.
5. Vakil N, van Zanten SV, Kahrilas P, et al: Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920.
6. Tack J, Caenepeel P, Arts J, et al: Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005;54:1370-1376.
7. Fass R: Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98(3 suppl):S2-S7.
8. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-664.
9. Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-979.
10. Barlow WJ, Orlando RC: The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 2005;128:771-778.
11. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R: Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537-545.
12. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP: Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995;37:457-464.
13. Bate CM, Griffin SM, Keeling PW, Axon AT, Dronfield MW, Chapman RW, et al: Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-555.
14. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-124.
15. Gardner JD, Gallo-Torres H, Sloan S, Robinson M, Miner PB: The basis for the decreased response to proton pump inhibitors in gastrooesophageal reflux disease patients without erosive oesophagitis. Aliment Pharmacol Ther 2003;18:891-905.
16. Kahrilas PJ, Lee TJ: Pathophysiology of gastroesophageal reflux disease. Thorac Surg Clin 2005;15:323-333.
17. Johnson LF, DeMeester TR: Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 1986;8(suppl 1):52-58.
18. Sifrim D, Holloway R, Silny J, Xin Z, Tack J, Lerut A, et al: Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001;120:1588-1598.
19. Cadiot G, Bruhat A, Rigaud D, Coste T, Vuagnat A, Benyedder Y, et al: Multivariate analysis of pathophysiological factors in reflux oesophagitis. Gut 1997;40:167-174.
20. Ho KY, Kang JY: Reflux esophagitis patients in Singapore have motor and acid exposure abnormalities similar to patients in the Western hemisphere. Am J Gastroenterol 1999;94:1186-1191.
21. Tobey NA, Hosseini SS, Caymaz-Bor C, Wyatt HR, Orlando GS, Orlando RC: The role of pepsin in acid injury to esophageal epithelium. Am J Gastroenterol 2001;96:3062-3070.
22. Emerenziani S, Sifrim D, Habib FI, Ribolsi M, Guarino MP, Rizzi M, et al: Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. Gut 2008;57:443-447.
23. Nagahara A, Miwa H, Minoo T, Hojo M, Kawabe M, Osada T, et al: Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol 2006;40:891-895.
24. Wu JC, Cheung CM, Wong VW, Sung JJ: Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:690-695.
25. Kern MK, Birn RM, Jaradeh S, Jesmanowicz A, Cox RW, Hyde JS, et al: Identification and characterization of cerebral cortical response to esophageal mucosal acid exposure and distention. Gastroenterology 1998;115:1353-1362.
26. Caviglia R, Ribolsi M, Maggiano N, et al: Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005;100:543-548.
27. Chen CC, Zimmer A, Sun WH, et al: A role for ASIC3 in the modulation of high-intensity pain stimuli. Proc Natl Acad Sci USA 2002;99:8992-8997.
28. Duan LJ, Wu LJ, Yu YQ, et al: Upregulation of acid-sensing ion channel ASIC1a in spinal dorsal horn neurons contributes to inflammatory pain hypersensitivity. J Neurosci 2007;27:11139-11148.
29. Wemmie JA, Coryell MW, Askwith CC, et al: Overexpression of acid-sensing ion channel 1a in transgenic mice increases acquired fear-related behavior. Proc Natl Acad Sci USA 2004;101:3621-3626.
30. Gao J, Duan B, Wang DG, et al: Coupling between NMDA receptor and acid-sensing ion channel contributes to ischemic neuronal death. Neuron 2005;48:635-646.
31. Xiong ZG, Pignataro G, Li M, et al: Acidsensing ion channels (ASICs) as pharmacological targets for neurodegenerative diseases. Curr Opin Pharmacol 2008;8:25-32.
32. Hunt RH, Armstrong D, Yaghoobi M, et al: Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008;28:187-199.
33. Smith JL, Opekun AR, Larkai E, Graham DY: Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989;96:683-689.
34. Hunt RH: Importance of pH control in the management of GERD. Arch Intern Med 1999;159:649-657.
35. Nagahama K, Yamato M, Nishio H, Takeuchi K: Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats. Dig Dis Sci 2006;51:303-309.
36. Goldberg HI, Dodds WJ, Gee S, Montgomery C, Zboralske FF: Role of acid and pepsin in acute experimental esophagitis. Gastroenterology 1969;56:223-230.
37. Gotley DC, Morgan AP, Ball D, Owen RW, Cooper MJ: Composition of gastro-oesophageal refluxate. Gut 1991;32:1093-1099.
38. Vaezi MF, Richter JE: Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 1995;117:699-704.
39. Lillemoe KD, Johnson LF, Harmon JW: Alkaline esophagitis: a comparison of the ability of components of gastroduodenal contents to injure the rabbit esophagus. Gastroenterology 1983;85:621-628.
40. Hunt RH: The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(suppl 1):3-7.
41. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-1810.
42. Talley NJ: Review article: gastro-oesophageal reflux disease - how wide is its span? Aliment Pharmacol Ther 2004;20(suppl 5):27-37;discussion 38-39.
43. Giamberardino MA: Recent and forgotten aspects of visceral pain. Eur J Pain 1999;3:77-92.
44. Drewes AM, Reddy H, Pedersen J, Funch-Jensen P, Gregersen H, Arendt-Nielsen L: Multimodal pain stimulations in patients with grade B oesophagitis. Gut 2006;55:926-932.
45. Trimble KC, Pryde A, Heading RC: Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995;37:7-12.
46. Rodriguez-Stanley S, Robinson M, Earnest DL, Greenwood-Van Meerveld B, Miner PB Jr: Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol 1999;94:628-631.
47. Fass R, Naliboff B, Higa L, Johnson C, Kodner A, Munakata J, et al: Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998;115:1363-1373.
48. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC: Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995;40:1607-1613.
49. Burdette BH, Gale EN: Pain as a learned response: a review of behavioral factors in chronic pain. J Am Dent Assoc 1988;116:881-885.
50. Ismail-Beigi F, Horton PF, Pope CE: Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970;58:163-174.
51. Ismail-Beigi F, Pope CE: Distribution of the histological changes of gastroesophageal reflux disease in the distal esophagus of man. Gastroenterology 1974;66:1109-1113.
52. Nakamura T, Shirakawa K, Masuyama H, et al: Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. Aliment Pharmacol Ther 2005;21 (suppl 2):19-26.
53. Hongo M: Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol 2006;41:95-99.
54. Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, et al: Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 2005;100:2299-2306.
55. Kiesslich R, Kanzler S, Vieth M, Moehler M, Neidig J, Thanka Nadar BJ, et al: Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy. Dig Dis 2004;22:221-227.
56. Tobey NA, Carson JL, Alkiek RA, et al: Dilated intercellular spaces: a morphological feature of acid reflux - damaged human esophageal epithelium. Gastroenterology 1996;111:1200-1205.
57. Calabrese C, Fabbri A, Bortolotti M, et al: Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003;18:525-532.
58. Caviglia R, Ribolsi M, Gentile M, et al: Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007;25:629-636.
59. Vieth M, Fiocca R, Haringsma J, et al: Radial distribution of dilated intercellular spaces of the esophageal squamous epithelium in patients with reflux disease exhibiting discrete endoscopic lesions. Dig Dis 2004;22:208-212.
60. Calabrese C, Bortolotti M, Fabbri A, Areni A, Cenacchi G, Scialpi C, et al: Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005;100:537-542.
61. van Malenstein H, Farré R, Sifrim D: Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2007, Epub ahead of print.
62. The Rome II International Working Teams: Functional heartburn;in Drossman DA, Corazziari E, Talley NJ, et al (eds): Rome II: The Functional Gastrointestinal Disorders, ed 2. Lawrence, Alle Press, 2000, pp 275-278.
63. Galmiche JP, Clouse RE, Bálint A, Cook IJ, Kahrilas PJ, Paterson WG, et al: Functional esophageal disorders. Gastroenterology 2006;130:1459-1465.
64. Fass R, Fennerty MB, Vakil N: Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001;96:303-314.
65. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
66. Johnsson F, Weywadt L, Solhaug JH, et al: One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:15-20.
67. Fass R, Ofman JJ, Gralnek IM, et al: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999;159:2161-2168.
68. Shapiro M, Green C, Bautista JM, et al: Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006;101:1084-1091.
69. Johnson LF, DeMeester TR: Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974;62:325-332.
70. Vitale GC, Cheadle WG, Sadek S, Michel ME, Cuschieri A: Computerized 24-hour ambulatory esophageal pH monitoring and esophagogastroduodenoscopy in the reflux patient. A comparative study. Ann Surg 1984;200:724-728.
71. Kahrilas PJ, Quigley EM: Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996;110:1982-1996.
72. Hirano I: Review article: modern technology in the diagnosis of gastro-oesophageal reflux disease - Bilitec, intraluminal impedance and Bravo capsule pH monitoring. Aliment Pharmacol Ther 2006;23(suppl 1):12-24.
73. Somani SK, Ghoshal UC, Saraswat VA, Aggarwal R, Misra A, Krishnani N, et al: Correlation of esophageal pH and motor abnormalities with endoscopic severity of reflux esophagitis. Dis Esophagus 2004;17:58-62.
74. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ: Acid reflux is a poor predictor for severity of erosive reflux esophagitis. Dig Dis Sci 2002;47:2565-2573.
75. Gardner JD, Rodriguez-Stanley S, Robinson M: Integrated acidity and the pathophysiology of gastroesophageal reflux disease. Am J Gastroenterol 2001;96:1363-1370.
76. Gardner JD, Sloan S, Miner PB, Robinson M: Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastrooesophageal reflux disease treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003;17:955-964.
77. Gledhill T, Buck M, Hunt RH: Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders. Gut 1984;25:1211-1216.
78. Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-767.
79. Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-1339.
80. Fackler WK, Ours TM, Vaezi MF, Richter JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-632.
81. Gardner JD, Sloan S, Robinson M, Miner PB: GERD subjects with increased nocturnal esophageal acidity have increased nocturnal gastric acidity. Am J Gastroenterol 2005;100(suppl 9):S24.
82. Katz PO, Castell DO, Chen Y, et al: Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004;20:399-406.
83. Miehlke S, Madisch A, Kirsch C, et al: Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily - a randomized, two-way crossover study. Aliment Pharmacol Ther 2005;21:963-967.
84. Hunt RH, Armstrong D, Yaghoobi M, et al: Inhibition of acid secretion by a novel proton pump inhibitor (PPI). Gastroenterology 2007;132(suppl 2):A486.
85. Richter JE: How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 2007;4:658-664.
86. Fass R, Shapiro M, Dekel R, et al: Systematic review: proton-pump inhibitor failure in gastrooesophageal reflux disease - where next? Aliment Pharmacol Ther 2005;22:79-94.
87. Bredenoord AJ, Smout AJ: Refractory gastrooesophageal reflux disease. Eur J Gastroenterol Hepatol 2008;20:217-223.
88. Hunt RH, Yuan Y, Mohammad Y: GERD: new strategies and new failures. J Clin Gastroenterol 2007;41(suppl 2):S72-S80.
89. Richter JE, Campbell DR, Kahrilas PJ, et al: Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-1809.